{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T10:53:35Z","timestamp":1793444015048,"version":"4.5.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Early detection and intervention research is expected to improve the outcomes for patients with high grade muscle invasive urothelial carcinoma (InvUC). With limited patients in suitable high-risk study cohorts, relevant animal model research is critical. Experimental animal models often fail to adequately represent human cancer. The purpose of this study was to determine the suitability of dogs with high breed-associated risk for naturally-occurring InvUC to serve as relevant models for early detection and intervention research. The feasibility of screening and early intervention, and similarities and differences between canine and human tumors, and early and later canine tumors were determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>STs (n=120) \u2265 6 years old with no outward evidence of urinary disease were screened at 6-month intervals for 3 years with physical exam, ultrasonography, and urinalysis with sediment exam. Cystoscopic biopsy was performed in dogs with positive screening tests. The pathological, clinical, and molecular characteristics of the \u201cearly\u201d cancer detected by screening were determined. Transcriptomic signatures were compared between the early tumors and published findings in human InvUC, and to more advanced \u201clater\u201d canine tumors from STs who had the typical presentation of hematuria and urinary dysfunction. An early intervention trial of an oral cyclooxygenase inhibitor, deracoxib, was conducted in dogs with cancer detected through screening.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Biopsy-confirmed bladder cancer was detected in 32 (27%) of 120 STs including InvUC (n=29, three starting as dysplasia), grade 1 noninvasive cancer (n=2), and carcinoma <jats:italic>in situ<\/jats:italic> (n=1). Transcriptomic signatures including druggable targets such as EGFR and the PI3K-AKT-mTOR pathway, were very similar between canine and human InvUC, especially within luminal and basal molecular subtypes. Marked transcriptomic differences were noted between early and later canine tumors, particularly within luminal subtype tumors. The deracoxib remission rate (42% CR+PR) compared very favorably to that with single-agent cyclooxygenase inhibitors in more advanced canine InvUC (17-25%), supporting the value of early intervention.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study defined a novel naturally-occurring animal model to complement experimental models for early detection and intervention research in InvUC. Research incorporating the canine model is expected to lead to improved outcomes for humans, as well as pet dogs, facing bladder cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1011969","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T07:56:54Z","timestamp":1668153414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Identification of a naturally-occurring canine model for early detection and intervention research in high grade urothelial carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Deepika","family":"Dhawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Ramos-Vara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar M.","family":"Utturkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Ruple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Tersey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce\u00a0R.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hock Gan","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Ostrander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi G.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry G.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Fulkerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael O.","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty\u00a0L.","family":"Bonney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Royce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey M.","family":"Fourez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Enstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth A.","family":"Ambrosius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah W.","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/cts.12577","article-title":"The current status of drug discovery and development as originated in united states academia: The influence of industrial and academic collaboration on drug discovery and development","volume":"11","author":"Takebe","year":"2018","journal-title":"Clin Transl Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00770","article-title":"Accelerating therapeutics for opportunities in medicine: A paradigm shift in drug discovery","volume":"11","author":"Hinkson","year":"2020","journal-title":"Front Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B4","article-title":"Lost in translation: animal models and clinical trials in cancer treatment","volume":"6","author":"Mak","year":"2014","journal-title":"Am J Transl Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrc3858","article-title":"Modelling bladder cancer in mice: Opportunities and challenges","volume":"15","author":"Kobayashi","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/17460441.2016.1174690","article-title":"Challenges with in vitro and in vivo experimental models of urinary bladder cancer for novel drug discovery","volume":"11","author":"Oliveira","year":"2016","journal-title":"Expert Opin Drug Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17714","article-title":"Insights from animal models of bladder cancer: Recent advances, challenges, and opportunities","volume":"8","author":"John","year":"2017","journal-title":"Oncotarget"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving human cancer therapy through the evaluation of pet dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01493","article-title":"Naturally-occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans","volume":"9","author":"Knapp","year":"2020","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-201523","article-title":"Basal and luminal molecular subtypes in naturally-occurring canine urothelial carcinoma are associated with tumor immune signatures and dog breed","volume":"7","author":"Sommer","year":"2021","journal-title":"Bladder Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.tvjl.2018.08.008","article-title":"Companion animals in comparative oncology: One medicine in action","volume":"240","author":"Garden","year":"2018","journal-title":"Vet J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112727","article-title":"Comparative pathobiology of canine and human prostate cancer: state of the art and future directions","volume":"14","author":"Nascente","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.pmbts.2021.12.003","article-title":"Canine models of human cancer: Bridging the gap to improve precision medicine","volume":"189","author":"Nance","year":"2022","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/03009858221092017","article-title":"Review: NF-kB activation in canine cancer","volume":"59","author":"Schlein","year":"2022","journal-title":"Vet Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/03009858221083038","article-title":"Canine and murine models of osteosarcoma","volume":"59","author":"Beck","year":"2022","journal-title":"Vet Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.773420","article-title":"Cancer-immunity cycle and therapeutic interventions- opportunities for including pet dogs with cancer","volume":"11","author":"Von Rueden","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101269","article-title":"Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies","volume":"15","author":"Capodanno","year":"2022","journal-title":"Transl Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009450","article-title":"Transcriptomic profiling in canines and humans reveals cancer specific gene modules and biological mechanisms common to both species","volume":"17","author":"Tawa","year":"2021","journal-title":"PloS Comput Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15347","article-title":"Large Animal models of glioma: current status and future prospects","volume":"41","author":"Hicks","year":"2021","journal-title":"Anticancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","article-title":"Dogs as a model for cancer","volume":"4","author":"Gardner","year":"2016","journal-title":"Annu Rev Anim Biosci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000161","article-title":"The comparative oncology trials consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway","volume":"6","author":"Gordon","year":"2009","journal-title":"PloS Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2018.01.012","article-title":"Canine sarcomas as a surrogate for the human disease","volume":"188","author":"Gustafson","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030799","article-title":"Strengths and weaknesses of pre-clinical models for human melanoma treatment: dawn of dogs\u2019 revolution for immunotherapy","volume":"19","author":"Barutello","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02360-6","article-title":"Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy","volume":"68","author":"Tarone","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0075-9","article-title":"Cancer prevention and screening: the next step in the era of precision medicine","volume":"3","author":"Loomans-Kropp","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5020034","article-title":"The role of angiogenesis in cancer treatment","volume":"5","author":"Rajabi","year":"2017","journal-title":"Biomedicines"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ilu018","article-title":"Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development","volume":"55","author":"Knapp","year":"2014","journal-title":"ILAR J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104703","article-title":"Origins of bladder cancer","volume":"11","author":"Czerniak","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061396","article-title":"Imaging and management of bladder cancer","volume":"13","author":"Wong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2020.105571","article-title":"Evaluation of epithelial and mesenchymal cell markers in canine urinary bladder transitional cell carcinoma","volume":"266","author":"Shinada","year":"2020","journal-title":"Vet J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.558978","article-title":"A comparative meta-analysis and in silico analysis of differentially expressed genes and proteins in canine and human bladder cancer","volume":"7","author":"Vitti Gambim","year":"2020","journal-title":"Front Vet Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12885-018-4409-3","article-title":"Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-seq","volume":"18","author":"Maeda","year":"2018","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007571","article-title":"Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer","volume":"14","author":"Dhawan","year":"2018","journal-title":"PloS Genet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1541-7786.MCR-14-0689","article-title":"Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer\u2013evidence for a relevant model system and urine-based diagnostic test","volume":"13","author":"Decker","year":"2015","journal-title":"Mol Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144170","article-title":"Detection of BRAF mutation in urine DNA as a molecular diagnostic for canine urothelial and prostatic carcinoma","volume":"10","author":"Mochizuki","year":"2015","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.049","article-title":"Targeted exome sequencing of the cancer genome in patients with very high-risk bladder cancer","volume":"70","author":"Longo","year":"2016","journal-title":"Eur Urol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165670","article-title":"Evolution of urothelial bladder cancer in the context of molecular classifications","volume":"21","author":"Minoli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular subtypes of bladder cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/ilar\/ilu017","article-title":"Domestic dogs and cancer research: a breed-based genomics approach","volume":"55","author":"Davis","year":"2014","journal-title":"ILAR J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-150044","article-title":"A nonselective cyclooxygenase inhibitor enhances the activity of vinblastine in a naturally-occurring canine model of invasive urothelial carcinoma","volume":"2","author":"Knapp","year":"2016","journal-title":"Bladder Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04229-0","article-title":"Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs","volume":"12","author":"Maeda","year":"2022","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32719","article-title":"A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera","volume":"146","author":"Jack","year":"2020","journal-title":"Int J Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26455","article-title":"Phase I\/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma","volume":"9","author":"Szigetvari","year":"2018","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12917-016-0882-6","article-title":"A pilot study of toceranib\/vinblastine therapy for canine transitional cell carcinoma","volume":"12","author":"Rippy","year":"2016","journal-title":"BMC Vet Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0049","article-title":"Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder","volume":"9","author":"Dhawan","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2020.106409","article-title":"Prostaglandin E2 as a therapeutic target in bladder cancer: from basic science to clinical trials","volume":"148","author":"Woolbright","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.2460\/javma.239.8.1084","article-title":"Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder","volume":"239","author":"McMillan","year":"2011","journal-title":"J Am Vet Med Assoc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12013","article-title":"Randomized trial of cisplatin versus firocoxib versus cisplatin\/firocoxib in dogs with transitional cell carcinoma of the urinary bladder","volume":"27","author":"Knapp","year":"2013","journal-title":"J Vet Intern Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.2003.64.1017","article-title":"Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs","volume":"64","author":"Henry","year":"2003","journal-title":"Am J Vet Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2017.12.008","article-title":"Vet J Evaluation of two-dimensional ultrasonography and computed tomography in the mapping and measuring of canine urinary bladder tumors","volume":"232","author":"Honkisz","year":"2018"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1159\/000446270","article-title":"The Paris system for reporting urinary cytology: the quest to develop a standardized terminology","volume":"60","author":"Barkan","year":"2016","journal-title":"Acta Cytol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0893","article-title":"Phase I\/II trial of vemurafenib in dogs with naturally occurring, BRAF-mutated urothelial carcinoma","volume":"20","author":"Rossman","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.01.008","article-title":"Histologic grading of urothelial carcinoma: a reappraisal","volume":"43","author":"Cheng","year":"2012","journal-title":"Hum Pathol"},{"key":"B57","volume-title":"TNM classification of tumours in domestic animals","author":"Owen","year":"1980"},{"key":"B58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13059-018-1536-8","article-title":"Clust: automatic extraction of optimal co-expressed gene clusters from gene expression data","volume":"19","author":"Abu-Jamous","year":"2018","journal-title":"Genome Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non-t-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2014.11.002","article-title":"TCGA muscle invasive bladder cancer analysis working group. the cancer genome atlas project on muscle-invasive bladder cancer","volume":"1","author":"Lerner","year":"2015","journal-title":"Eur Urol Focus"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/vco.283","article-title":"Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"B64","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-18539-2","volume-title":"Fundamentals of clinical trials, 5th edition","author":"Friedman","year":"2015"},{"key":"B65","first-page":"28","article-title":"Mortality in Scottish terriers, correlations with cancer incidence","volume":"3","author":"Leith","year":"2007","journal-title":"Bagpiper Scottish Terrier Club America"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2013.07.046","article-title":"Bias in breast cancer research in the screening era","volume":"22","author":"Cox","year":"2013","journal-title":"Breast"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/vru.13051","article-title":"Ultrasonographic detection of apex nodules in the urinary bladder of Scottish terriers","volume":"63","author":"Heng","year":"2022","journal-title":"Vet Radiol Ultrasound"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.758612","article-title":"Development and validation of a six-gene prognostic signature for bladder cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Front Genet"},{"key":"B69","article-title":"Overexpressed gene signature of EPH receptor A\/B family in cancer patients-comprehensive analyses from the public high-throughput database","volume":"13","author":"Phan","year":"2020","journal-title":"Int J Clin Exp Pathol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071795","article-title":"Molecularly targeted therapy towards genetic alterations in advanced bladder cancer","volume":"14","author":"Thomas","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236040","article-title":"Alterations of chromatin regulators in the pathogenesis of urinary bladder urothelial carcinoma","volume":"13","author":"Hoffmann","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123089","article-title":"A comprehensive bioinformatics analysis of notch pathways in bladder cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B73","article-title":"The hippo pathway: An emerging role in urologic cancers","volume":"9","author":"Cinar","year":"2021","journal-title":"Am J Clin Exp Urol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.1971035","article-title":"Genome-wide screening for the G-protein-coupled receptor (GPCR) pathway-related therapeutic gene RGS19 (regulator of G protein signaling 19) in bladder cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Bioengineered"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01429","article-title":"Classification of muscle-invasive bladder cancer based on immunogenomic profiling","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2011.00684.x","article-title":"Effects of carprofen, meloxicam and deracoxib on platelet function in dogs","volume":"39","author":"Mullins","year":"2012","journal-title":"Vet Anaesth Analg"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ph11040101","article-title":"Cyclooxygenase-1 (COX-1) and COX-1 inhibitors in cancer: a review of oncology and medicinal chemistry literature","volume":"11","author":"Pannunzio","year":"2018","journal-title":"Pharm (Basel)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/vco.12470","article-title":"The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxil) exerts anti-tumour effects in vitro independent of cyclooxygenase-2 expression levels","volume":"17","author":"Hurst","year":"2019","journal-title":"Vet Comp Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-020-0966-5","article-title":"Blue light cystoscopy: Indications and outcomes","volume":"21","author":"Pohar","year":"2020","journal-title":"Curr Urol Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-12-0358","article-title":"Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo","volume":"6","author":"Cekanova","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0315","article-title":"Adjuvant sirolimus does not improve outcome in pet dogs receiving standard-of-care therapy for appendicular osteosarcoma: a prospective, randomized trial of 324 dogs","volume":"27","author":"LeBlanc","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12885-018-4059-5","article-title":"Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer","volume":"18","author":"Pulido","year":"2018","journal-title":"BMC Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09101.x","article-title":"A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results","volume":"106","author":"Pruthi","year":"2010","journal-title":"BJU Int"},{"key":"B84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1011969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T07:57:00Z","timestamp":1668153420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1011969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":84,"alternative-id":["10.3389\/fonc.2022.1011969"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1011969","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"article-number":"1011969"}}